Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jhep.2008.08.010
DC FieldValue
dc.titleABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
dc.contributor.authorJasinghe, V.J.
dc.contributor.authorXie, Z.
dc.contributor.authorZhou, J.
dc.contributor.authorKhng, J.
dc.contributor.authorPoon, L.-F.
dc.contributor.authorSenthilnathan, P.
dc.contributor.authorChen, C.-S.
dc.contributor.authorAlbert, D.H.
dc.contributor.authorDavidsen, S.K.
dc.date.accessioned2011-09-27T05:15:56Z
dc.date.available2011-09-27T05:15:56Z
dc.date.issued2008
dc.identifier.citationJasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K. (2008). ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Journal of Hepatology 49 (6) : 985-997. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2008.08.010
dc.identifier.issn01688278
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26815
dc.description.abstractBackground/Aims: Receptor tyrosine kinase inhibitors (RTKIs) and mTOR inhibitors are potential novel anticancer therapies for HCC. We hypothesized that combination targeted on distinctive signal pathways would provide synergistic therapeutics. Methods: ABT-869, a novel RTKI, and rapamycin were investigated in HCC pre-clinical models. Results: Rapamycin, but not ABT-869, inhibited in vitro growth of Huh7 and SK-HEP-1 HCC cells in a dose dependant manner. However, in subcutaneous Huh7 and SK-HEP-1 xenograft models, either ABT-869 or rapamycin can significantly reduce tumor burden. Combination treatment reduced the tumors to the lowest volume (95 ± 20 mm3), and was significantly better than single agent treatment (p < 0.05). Immunohistochemical staining of tumor shows that ABT-869 potently inhibits VEGF in HCC in vivo. In addition, the MAPK signaling pathway has been inhibited by significant inhibition of phosphorylation of p44/42 MAP kinase by ABT-869 in vivo. Rapamycin inhibits phosphorylation of p70 S6 kinase and 4E-BP-1, downstream targets of mTOR, and decreases VEGF. Combination treatment showed synergistic effect on expression levels of p27 in vivo. Dramatic inhibition of neo-angiogenesis by ABT-869 was also demonstrated. Conclusions: HCC could potentially be treated with the combination treatment of ABT-869 and rapamycin. Clinical trials on combination therapy are warranted. © 2008 European Association for the Study of the Liver.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.jhep.2008.08.010
dc.sourceScopus
dc.subjectABT-869
dc.subjectAngiogenesis
dc.subjectHepatocellular carcinoma
dc.subjectmTOR pathway
dc.subjectRapamycin
dc.subjectTyrosine kinase inhibitor
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.jhep.2008.08.010
dc.description.sourcetitleJournal of Hepatology
dc.description.volume49
dc.description.issue6
dc.description.page985-997
dc.identifier.isiut000261708600014
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.